Form 4: Galectin CEO Exercises Options, Sells Shares

Galectin Therapeutics CEO Joel Lewis exercised stock options and subsequently sold a portion of common stock under a pre-arranged 10b5-1 plan.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc. (GALT), reported transactions involving the exercise of stock options and the sale of common stock.
• On November 10, 2025, Lewis acquired 1,867 shares of common stock by exercising stock options at a price of $2.39 per share.
• Concurrently, Lewis disposed of 1,867 shares of common stock at a weighted average sale price of $6.0269 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 plan adopted by Lewis on April 17, 2025, and previously disclosed in the Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025.
• Following these transactions, Lewis directly beneficially owns 832,592 shares of common stock.
• Lewis also indirectly holds 2,000 shares as a USTA custodian for a minor child, disclaiming beneficial ownership of these shares.
• Remaining derivative securities include 22,363 stock options with an exercise price of $2.39, which vested 100% on December 14, 2018, and expire on December 14, 2027.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) under a Rule 10b5-1 plan, which does not inherently indicate positive or negative sentiment regarding the company's future prospects.

Positives

• The insider transaction resulted in a profit for the CEO, as options were exercised at $2.39 and shares were sold at a weighted average of $6.0269.
• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating that the sale was scheduled in advance and not based on immediate, undisclosed material information.

Negatives

• The sale of shares by a key executive, even if pre-planned, can sometimes be perceived cautiously by investors, though the amount is relatively small.

Future Outlook

This Form 4 filing is a transactional report of insider activity and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Industry Context

This filing reports a routine insider transaction and does not provide information that directly relates to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and trading activity, which is a standard disclosure for publicly traded companies. The small scale of the transaction is unlikely to have a significant impact on shareholder sentiment.
• Employees: No direct impact on employees is indicated by this transactional filing.

Key Dates

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, CEO, Stock Sale